Skip to Content
Merck
  • Transplacental carcinogenesis with dibenzo[def,p]chrysene (DBC): timing of maternal exposures determines target tissue response in offspring.

Transplacental carcinogenesis with dibenzo[def,p]chrysene (DBC): timing of maternal exposures determines target tissue response in offspring.

Cancer letters (2011-11-17)
Lyndsey E Shorey, David J Castro, William M Baird, Lisbeth K Siddens, Christiane V Löhr, Melissa M Matzke, Katrina M Waters, Richard A Corley, David E Williams
ABSTRACT

Dibenzo[def,p]chrysene (DBC) is a transplacental carcinogen in mice (15mg/kg; gestation day (GD) 17). To mimic residual exposure throughout pregnancy, dams received four smaller doses of DBC (3.75mg/kg) on GD 5, 9, 13 and 17. This regimen alleviated the previously established carcinogenic responses in the thymus, lung, and liver. However, there was a marked increase in ovarian tumors (females) and hyperplastic testes (males). [(14)C]-DBC (GD 17) dosing revealed transplacental distribution to fetal tissues at 10-fold lower concentrations than in paired maternal tissue and residual [(14)C] 3weeks post-dose. This study highlights the importance of developmental stage in susceptibility to environmental carcinogens.

MATERIALS
Product Number
Brand
Product Description

Dibenzo[a,l]pyrene, BCR®, certified reference material
Supelco
Dibenzo[a,l]pyrene, vial of 25 mg, Cerilliant®